Vinodh R. Nannan Panday

Hypersensitivity Reactions to the Taxanes Paclitaxel and Docetaxel

Vinodh R. Nannan Panday, Manon Huizing, W.W. ten Bokkel Huinink et al. · Clinical Drug Investigation · 1997 · 52 citations

Drug Hypersensitivity, Taxanes Paclitaxel, Allergy +7

Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer

Virginie M.M. Herben, Vinodh R. Nannan Panday, Dick J. Richel et al. · Journal of Clinical Oncology · 1999 · 43 citations

Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma – drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study

Vinodh R. Nannan Panday, Richard M. W. Hoetelmans, Rolf P. G. van Heeswijk et al. · Cancer Chemotherapy and Pharmacology · 1999 · 23 citations

Protease Inhibitors, Medicine, Immunology +10

PHARMACOKINETICS OF PACLITAXEL ADMINISTERED AS A 3-HOUR OR 96-HOUR INFUSION

Vinodh R. Nannan Panday, W.W. ten Bokkel Huinink, Jan B. Vermorken et al. · Pharmacological Research · 1999 · 18 citations

Pharmacology, Clinical Pharmacology, Pharmacotherapy +2

Carboplatin Dosage Formulae Can Generate Inaccurate Predictions of Carboplatin Exposure in Carboplatin/Paclitaxel Combination Regimens

Vinodh R. Nannan Panday, L.J.C. van Warmerdam, Manon Huizing et al. · Clinical Drug Investigation · 1998 · 15 citations

Carboplatin Exposure, Carboplatin/paclitaxel Combination Regimens, Oncology +8